Chief Executive Officer, Pfizer
Appears in 1 story
Leading Pfizer's regulatory submission strategy for the Lyme vaccine
The last Lyme disease vaccine was pulled from the market in 2002 after unfounded safety fears destroyed demand. Twenty-four years later, Pfizer and French biotech Valneva announced that their replacement candidate showed 73% efficacy in a Phase 3 trial of 9,000+ participants. They will seek FDA approval this year for a possible 2027 launch.
Updated May 30
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
